LL-37 vs Enfuvirtide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Also: Fuzeon, T-20
A peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.
Key Comparison Insights
- Enfuvirtide is FDA approved, while LL-37 remains in research stages.
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Enfuvirtide has stronger research evidence (FDA Approved) compared to LL-37 (Human Trials).
Detailed Comparison
| Attribute | LL-37 | Enfuvirtide |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. | Enfuvirtide is a 36-amino acid peptide that binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion. This blocks HIV entry before the virus can infect the cell. |
| Common Dosing | 100-200 mcg daily Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection or topical | Subcutaneous injection twice daily |
| Typical Duration | Variable by protocol | Ongoing as part of HIV regimen |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. | TORO trials showed significant viral load reduction in treatment-experienced patients. Reserved for salvage therapy due to twice-daily injection requirement and injection site reactions. |
Frequently Asked Questions: LL-37 vs Enfuvirtide
What is the difference between LL-37 and Enfuvirtide?
LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. Enfuvirtide is a immune peptide that a peptide hiv fusion inhibitor that blocks viral entry into cells. first approved drug in the fusion inhibitor class. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or Enfuvirtide?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while Enfuvirtide is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and Enfuvirtide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and Enfuvirtide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of LL-37 and Enfuvirtide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.